RE:RE:RE:Pressure on stock price.................
I don't expect perfect results either, but based on the 70+% CR rate of "evaluable" patients to date who received at least one optimized treatment (11 in total), I selfishly expect at least "near-perfect" results for those patients who receive "two" optimized treatments. Imo, that 70+% 90 day CR rate for that sample size is very likely not a statistical fluke.
I'm also encouraged by the fact that of the two patients who initially received an unoptimized primary treatment, one patient coverted from NR to CR status after receiving a subsequent optimized maintenance treatment. This not only indicates the enhanced efficacy of an optimized treatment, but also points to the significant value a future maintenance dose, or two, can offer to the partial responder & the more resistant PR, respectively...resistant PR meaning a patient's PR status persists >90-180 days after a single optimized maintenance treatment.
It is not unreasonable to also think a good percentage of resistant non-responders could ultimately respond if simply given an additional optimized treatment, or if a certain treatment enhancement(s) is made in the form of a dosage adjustment, etc. In the future, it is possible docs find out in practice that the current "two" treatment protocol is simply not sufficient in select cases. JMO.